A Phase 1b Trial of X4P-001 Alone and With Pembrolizumab in Patients With Advanced Melanoma
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2017
At a glance
- Drugs X4P 001 (Primary) ; Pembrolizumab
- Indications Malignant melanoma
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors X4 Pharmaceuticals
- 11 Jan 2017 Planned End Date changed from 1 May 2017 to 1 Oct 2017.
- 11 Jan 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
- 27 Sep 2016 First patient has been enrolled in this trial. Preliminary results from the study are expected in 2017, as reported by a X4 Pharmaceuticals media release